（原标题：一脉阳光(02522)：影禾医脉发布全球首个基座大模型驱动的AI辅助诊断产品） 智通财经APP讯，一脉阳光(02522)公布，2025年10月16日，由集团参股孵化的人工智能公司上海影禾医 脉智能科技有限公司(影禾医脉)，正式发布全球首个基于医学影像基座大模型"影禾觅芽"研发的AIR(路 径级AI辅助诊断产品)——胸部CT平扫辅助诊断 AIR。AIR产品标志着医学影像AI正式从"单病种小模 型"的1.0时代，迈入"基座大模型驱动"的2.0时代，具备全病灶、全病种、多器官协同诊断能力，是医学 影像智能诊断领域的一项里程碑式突破。 AIR产品以扫描部位为诊断单元，首款落地产品聚焦胸部CT平扫，实现一次扫描即可同步完成肺、胸 膜、纵隔等多器官的全病灶检测与诊断，覆盖该部位所有常见病种。AIR产品基于全球首个跨模态、全 流程医学影像基座大模型"影禾觅芽"开发，具备多器官联动分割能力，充分体现了其高效诊断、精准覆 盖、交互协同、无缝集成的技术优势，从根本上重构了医学影像AI的研发与应用逻辑。 AIR产品不仅是一款诊断工具，更是影禾医脉基座大模型生态的首个商业化落地成果。通过开放接口连 接顶级医院与基层医疗机构 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Jiangxi Rimag Group Co., Ltd. 江西一脈陽光集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2522） 自願公告 影禾醫脈發佈全球首個基座大模型驅動的AI輔助診斷產品 本公告由江西一脈陽光集團股份有限公司（「本公司」，連同其附屬公司統稱為「本 集團」）董事（「董事」）會（「董事會」）自願作出。 董事會欣然宣佈，2025年10月16日，由本集團參股孵化的人工智能公司上海影 禾醫脈智能科技有限公司（「影禾醫脈」），正式發佈全球首個基於醫學影像基座大 模型「影禾覓芽®」研發的AIR（路徑級AI輔助診斷產品）——胸部CT平掃輔助診斷 AIR（「AIR產品」）。AIR產品標誌着醫學影像AI正式從「單病種小模型」的1.0時 代，邁入「基座大模型驅動」的2.0時代，具備全病灶、全病種、多器官協同診斷 能力，是醫學影像智能診斷領域的一項里程碑式突破。 AIR產品不僅 ...

Core Viewpoint - The company, Yipai Yangguang (02522), has announced a share placement to raise approximately HKD 562 million, with a focus on expanding its capabilities in data and artificial intelligence within the medical imaging sector [1] Group 1: Share Placement Details - Yipai Yangguang plans to place 35 million shares at a discount of about 12.53%, aiming to raise net proceeds of approximately HKD 562 million [1] - Approximately 40% of the net proceeds will be allocated to the development of data and AI capabilities, specifically in medical imaging data mining, annotation, and cleaning [1] - About 30% of the net proceeds will be used for expanding the company's medical imaging center business through self-investment or acquisitions, targeting both domestic and overseas markets, including Hong Kong and Singapore [1] Group 2: Financial Performance - For the six months ending June 30, 2025, the company reported revenue of RMB 467 million, a year-on-year increase of 12.89% [1] - Gross profit was reported at RMB 137 million, with a significant increase in net profit attributable to shareholders of RMB 16.44 million, reflecting a year-on-year growth of 328.65% [1] - The company anticipates that its newly established imaging center projects will gradually commence operations in the second half of 2025, coinciding with the expected recovery of national medical equipment update demands by the end of 2024 [1]

Core Viewpoint - The company, Yipai Yangguang (02522), has announced a share placement to raise approximately HKD 562 million, with a discount of about 12.53%, to fund its development in data and artificial intelligence, as well as to expand its medical imaging business [1] Group 1: Share Placement and Fund Allocation - Yipai Yangguang plans to place 35 million shares at a discount of approximately 12.53%, aiming to raise net proceeds of about HKD 562 million [1] - Approximately 40% of the net proceeds will be allocated to the development of data and AI capabilities, focusing on medical imaging data mining, annotation, and cleaning services [1] - About 30% of the net proceeds will be used for expanding the company's medical imaging center business and enabling solution services through self-investment or acquisitions, targeting both domestic and overseas markets, including Hong Kong and Singapore [1] Group 2: Financial Performance - For the six months ending June 30, 2025, the company reported revenue of RMB 467 million, representing a year-on-year increase of 12.89% [1] - Gross profit was reported at RMB 137 million, with a significant increase in net profit attributable to shareholders of RMB 16.44 million, up 328.65% year-on-year [1] - The company anticipates that its newly established imaging center projects will gradually commence operations in the second half of 2025, benefiting from the ongoing release of national medical infrastructure policies [1]

Core Viewpoint - The company, Yipai Yangguang (02522.HK), has announced a placement agreement to issue 35 million shares at a price of HKD 16.76 per share, which represents approximately 13.55% of the existing H-shares and 9.58% of the total issued shares as of the announcement date [1][2]. Group 1 - The placement is expected to raise approximately HKD 586.6 million in total proceeds, with a net amount of about HKD 562.1 million after expenses [2]. - The net proceeds from the placement will be allocated as follows: approximately 40% for the development of data and artificial intelligence in medical imaging, 30% for expanding the medical imaging center business through investments or acquisitions, 20% for establishing an incubation fund for quality healthcare enterprises, and 10% for general working capital [2]. Group 2 - The company aims to deepen its capabilities in data services related to medical imaging by collaborating with leading enterprises in AI and healthcare, as well as major hospitals in China [2]. - The strategic focus includes establishing a data space and creating a convertible imaging center, while also building an investment portfolio in high-quality enterprises within the medical field [2].

Group 1 - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for 17 companies, including Deshi Biotech, regarding their overseas listing applications [1] - Deshi Biotech submitted its listing application to the Hong Kong Stock Exchange on June 29, 2025, with Huatai International as the sole sponsor [1] - The CSRC requires Deshi Biotech to clarify its business scope and whether it involves any foreign investment restrictions, particularly in areas like human stem cells and gene diagnosis and treatment [1][2] Group 2 - Deshi Biotech's iMedImage is recognized as the world's largest general medical imaging base model and has achieved commercialization [2] - The iMedImage model supports 19 types of medical imaging modalities and covers over 90% of clinical medical imaging scenarios, including reproductive health and hematological malignancies [2] - The solutions provided by iMedImage significantly reduce R&D costs and time to market, addressing uneven distribution of medical resources and improving diagnostic efficiency [2]

Group 1 - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for 17 companies, including Deshi Biotech, regarding their overseas listing applications [1][2] - Deshi Biotech submitted its listing application to the Hong Kong Stock Exchange on June 29, 2025, with Huatai International as the sole sponsor [1] - The CSRC has requested Deshi Biotech to clarify its business scope and whether it involves any foreign investment restrictions, particularly in areas like human stem cells and gene diagnosis and treatment [1][2] Group 2 - Deshi Biotech's proprietary iMedImageTM is recognized as the world's largest general medical imaging base model and has been commercialized successfully [2] - The iMedImageTM model supports 19 types of medical imaging modalities and covers over 90% of clinical medical imaging scenarios, enhancing diagnostic efficiency and addressing uneven distribution of medical resources [2] - The company focuses on AI solutions for medical imaging, which significantly reduce R&D costs and time to market, providing scalable innovative pathways for smart healthcare [2]

Core Viewpoint - Hangzhou Deshi Bio is leading the AI medical diagnosis sector with its self-developed iMedImage universal medical imaging model, aiming for an IPO in Hong Kong with a valuation of 2.56 billion yuan after the latest funding round [1] Group 1: iMedImage Model and Market Potential - iMedImage is designed to address the challenges in the medical imaging market, which is projected to reach 180 billion yuan in China by 2030, with AI in medical imaging being one of the fastest-growing segments globally [1][5] - The model significantly reduces development time from the industry average of 3-5 years to under 60 days and cuts AI R&D costs by over 90% [1][3] - The model's architecture allows for the creation of specialized models with only 200 image samples, drastically lowering data requirements compared to traditional methods [3] Group 2: Competitive Advantages and Innovations - iMedImage provides a comprehensive solution that includes six AI analysis systems, three AI medical devices, and various model services, positioning the company as a leader in the market with a 30.6% share in 2024 [5][6] - The platform supports cross-modal compatibility and can handle 19 types of medical imaging modalities, covering over 90% of clinical scenarios [6] - The accuracy of diagnostic systems using iMedImage has improved from an average of 50% to 99.45%, and the time to generate clinical reports has been reduced from nearly 30 days to just 4 days [6] Group 3: Financial Performance and Growth - The company reported revenues of 52.84 million yuan in 2023 and 70.35 million yuan in 2024, with a 33.1% year-on-year growth in cloud service revenue [7] - The gross margin for products has consistently exceeded 65%, indicating strong market acceptance and technological premium [7] - The net loss for 2024 is projected to be approximately 43.38 million yuan, a reduction of nearly 23% from the previous year, reflecting robust growth momentum [7] Group 4: Future Development and Strategic Goals - The company plans to use the funds raised for the development and commercialization of its core product, AI AutoVision, and further iterations of the iMedImage model [8] - The strategic goal is to transition from an "AI tool provider" to a "full-modal medical AI infrastructure architect," aiming to share AI benefits across all device manufacturers and clinical hospitals [8]

Core Viewpoint - Deshi Biotech has submitted an application for listing on the Hong Kong Stock Exchange, focusing on the AI medical imaging sector, with a leading market share in chromosome karyotype analysis in China [1][2] Company Overview - Founded in September 2016, Deshi Biotech specializes in the AI medical imaging industry and ranks first in the chromosome karyotype analysis field in China with a market share of 30.6% as of 2024 [1] - The company’s main revenue comes from low-tech Class II and I medical devices, while the commercial value of its core AI products remains to be validated [1][2] Market Potential - The AI-driven medical imaging market in China is projected to grow from RMB 100 million in 2019 to RMB 2.4 billion in 2024, with an estimated CAGR of 60.2% from 2024 to 2030, reaching RMB 40.1 billion by 2030 [1][2] Product Analysis - Key products include the iMedImage general medical imaging base model and the AI AutoVision chromosome karyotype analysis system, which is expected to receive Class III medical device registration by the end of 2025 [2][4] - Despite the emphasis on AI products, the majority of revenue is generated from lower "AI content" products [4][6] Financial Performance - Revenue for 2023 and 2024 was RMB 52.84 million and RMB 70.35 million, respectively, with losses of RMB 56.12 million and RMB 43.38 million [10] - The gross margin has significantly declined from 71.0% in 2023 to 65.5% in 2024, primarily due to increased contributions from lower-margin products [10][11] Cash Flow and Financial Health - The company has been experiencing cash flow issues, with cash reserves dropping to RMB 5.57 million by April 2025, raising concerns about its ability to sustain operations [11] - Trade receivables have increased significantly, indicating potential liquidity challenges [11]

Core Viewpoint - The company, Hangzhou Deshi Biotechnology Co., Ltd., is preparing for an IPO on the Hong Kong Stock Exchange amid challenges in its core business and financial pressures, despite its leading position in the chromosome karyotype analysis market and the potential of its AI-driven diagnostic system AI AutoVision® [1][10][20]. Company Overview - Founded by Dr. Song Ning, who has a strong academic background in computer science and medical genetics, the company has seen significant capital inflow since its establishment in 2016 [2][3]. - As of the latest funding round in June 2025, the company's post-money valuation reached 2.56 billion yuan [4]. Financial Performance - The company has faced declining revenue in its core business, with total revenue projected to reach 70.35 million yuan in 2024, while core business revenue dropped from 43.90 million yuan to 40.84 million yuan [12]. - The gross profit margin has significantly decreased by 19.9 percentage points to 56.7%, with consumables and reagents showing a drastic decline in gross margin from 43.1% to 5.6% [12]. - The company reported net losses of 56.12 million yuan and 43.38 million yuan for 2023 and 2024, respectively, with cash reserves dwindling to approximately 5.57 million yuan by April 2025 [19]. Market Position - Deshi Biotechnology holds a 30.6% market share in China's chromosome karyotype analysis system market, which is projected to grow from 120 million yuan in 2019 to 1.038 billion yuan by 2030 [11][12]. - The company is betting on the iMedImage medical imaging base model, which is expected to contribute significantly to revenue, with a projected market size of 51.9 billion yuan by 2035 [17][18]. Strategic Moves - The company has engaged in various share transfers and buybacks to maintain control, with Dr. Song Ning successfully regaining majority voting rights [3][4]. - Recently, the company sold two subsidiaries for 1 yuan each to streamline operations, raising questions about the financial health of these entities [9][10]. Future Prospects - The success of the AI AutoVision® system is critical for the company's future, as it has received "innovative medical device" recognition and is currently undergoing registration [20].